A Phase 3 interventional study of Pegvaliase and Diet Only in Phenylketonuria (PKU), sponsored by BioMarin Pharmaceutical. Active, not recruiting at 16 sites in 2 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by BioMarin Pharmaceutical · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing pegvaliase in Phenylketonurias — 1 open to participants now, 2 under way, 1 of them phase 3. pegvaliase · Phenylketonurias.
Among the 10 studies testing pegvaliase in Phenylketonurias, this one is the 4th largest by enrollment, is the only one that started in 2022, is one of 4 in phase 3, and was the 9th registered.
191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.
Browse Phenylketonurias studies →1 of the 10 studies testing pegvaliase in Phenylketonurias is open now, in 1 country. Recruiting first, the newest first:
BioMarin Pharmaceutical · Sites in United States
Ages 18–65
By country, each count listing its studies:
pegvaliase: first FDA approval 2018 (PALYNZIQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2022.
This study's enrollment of 55 is above the median of 27 across 122 interventional studies indexed under Phenylketonurias.
Median enrollment 39 across the 10 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 1 most frequent:
BioMarin Pharmaceutical is the lead sponsor of 112 studies on the registry; 13 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 12 (63%) have results posted.
35 studies in Phenylketonurias by BioMarin Pharmaceutical: 3 open now, 5 under way, 1 of them phase 3. Of 29 finished, 17 (59%) have results posted.
Among the 35 studies in Phenylketonurias by BioMarin Pharmaceutical, this one is the 14th largest by enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2022, is one of 11 in phase 3, and was the 31st registered.
BioMarin Pharmaceutical’s Phenylketonurias studies by the year they started, since 2004.
1 of the studies testing pegvaliase in Phenylketonurias that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477691BioMarin PharmaceuticalImmune Modulation During Palynziq® Treatment in Adults (IMPALA) | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing pegvaliase in Phenylketonurias, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among BioMarin Pharmaceutical’s 35 in Phenylketonurias:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3 open-label randomized controlled study enrolling approximately 54 adolescents with PKU. The study is designed to assess the safety and efficacy of pegvaliase injections.
This Phase 3 multicenter study is designed to evaluate the safety and efficacy of pegvaliase administered daily to adolescents (ages 12 to 17 years old (US), inclusive, and 12 to 15 years old (EU), inclusive 12-17) with phenylketonuria (PKU). Participants will be randomized in a 2:1 ratio to the active (pegvaliase) and control (diet-only) treatment arms, respectively, with 36 participants receiving pegvaliase and 18 participants managing their PKU with diet alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment Arm
Drug: Pegvaliase
Participants will be managing their PKU with diet alone. Participants in the diet-only control arm will be required to maintain and adjust dietary and medical protein food intake through Week 72, initiating pegvaliase treatment beginning Week 73 and, from Weeks 73 through 215.
Other: Diet Only
Pegvaliase 2.5mg/10mg/20mg/40mg/60mg self-administered from 1 time up to 7 times a week
Also known as: PEG PAL, BMN 165
Diet Control
Change From Baseline in Blood Phe Concentration Following 72 Weeks (Average of the Week 69 and Week 73) on Study.
The blood Phe measurement following 72 weeks on study is defined as the average of the Week 69 and Week 73 blood Phe measurements. Change from baseline in blood Phe will be compared between participants in the active (pegvaliase) and the control (diet-only) treatment arms. Baseline blood Phe concentration at Part 1 was defined as the average of 3 pre-treatment measurements collected between Screening/Run-in (2) and Day 1 pre-dose (1).
Time frame: Baseline to Week 72 (average of the Week 69 and Week 73)
Incidence of Treatment-emergent Adverse Events (Part 1)
Treatment-emergent adverse events (TEAE) is defined as any AE that newly appeared or worsened in severity after first dose of pegvaliase (pegvaliase arm) or on or after study day 1 (diet-only arm) until 30 days after last dose of the study. Serious adverse event (SAE).
Time frame: Up to Week 73
Percentage of Participants With Positive Anti-pegvaliase Total Antibody (TAb)
The anti-pegvaliase total antibody (TAb) method captures drug-binding antibodies comprised of different isotypes and specificities. Antibody Positivity = number of subjects testing positive at any study visit / total number of subjects at study visit. The baseline was defined as the last non-missing measurement collected prior to the first pegvaliase dose (pegvaliase arm) or prior to or on Visit 1 date (diet-only arm)
Time frame: Baseline (Day 1), Week 73
Percentage of Participants With Positive PAL IgG Antibody
The presence of immunoglobulin G (IgG) Antibodies against phenylalanine ammonia lyase (PAL) is measured overtime. The baseline was defined as the last non-missing measurement collected prior to the first pegvaliase dose (pegvaliase arm) or prior to or on Visit 1 date (diet-only arm)
Time frame: Baseline (Day 1), Week 73
Percentage of Participants With Positive PAL IgM Antibody
The presence of immunoglobulin M (IgM) Antibodies against PAL (phenylalanine ammonia lyase) is measured overtime. PAL IgM was positive if the titer value was greater than or equal to the median of all baseline PAL IgM titers. The baseline was defined as the last non-missing measurement collected prior to the first pegvaliase dose (pegvaliase arm) or prior to or on Visit 1 date (diet-only arm)
Time frame: Baseline (Day 1), Week 73
Percentage of Participants With Positive PEG IgG Antibody
The presence of IgG Antibodies against polyethylene glycol (PEG) is measured overtime The baseline was defined as the last non-missing measurement collected prior to the first pegvaliase dose (pegvaliase arm) or prior to or on Visit 1 date (diet-only arm)
Time frame: Baseline (Day 1), Week 73
Percentage of Participants With Positive PEG IgM Antibody
The presence of IgM Antibodies against PEG (polyethylene glycol) is measured overtime The baseline was defined as the last non-missing measurement collected prior to the first pegvaliase dose (pegvaliase arm) or prior to or on Visit 1 date (diet-only arm)
Time frame: Baseline (Day 1), Week 73
Percentage of Participants With Positive Neutralizing Antibodies (NAb)
Neutralizing antibodies (NAbs) capable of inhibiting the enzymatic activity of pegvaliase were measured. The baseline was defined as the last non-missing measurement collected prior to the first pegvaliase dose (pegvaliase arm) or prior to or on Visit 1 date (diet-only arm)
Time frame: Baseline (Day 1), Week 73
Change From Baseline in Total Dietary Protein Intake (i.e., Medical Food and/or Intact Food) Following 72 Weeks (Average of Week 69 and Week 73) on Study
The total dietary protein intake following 72 weeks on study is defined as the mean total dietary protein intake calculated from the 3-day diet diaries collected at Week 69 and Week 73 visits. Total dietary protein is measured in grams/kilogram (g/kg). Baseline total protein intake at Part 1 was defined as the mean total dietary protein intake calculated from the 3 separate 3-day diet diaries collected during Screening/Run-in (2) and Day 1 (1).
Time frame: Baseline to Week 72 (average of Week 69 and week 73)
Percentage Change From Baseline in Total Dietary Protein Intake (i.e., Medical Food and/or Intact Food) Following 72 Weeks (Average of Week 69 and Week 73) on Study
The total dietary protein intake following 72 weeks on study is defined as the mean total dietary protein intake calculated from the 3-day diet diaries collected at Week 69 and Week 73 visits. Total dietary protein is measured in grams/kilogram (g/kg). Baseline total protein intake at Part 1 was defined as the mean total dietary protein intake calculated from the 3 separate 3-day diet diaries collected during Screening/Run-in (2) and Day 1 (1).
Time frame: Baseline to Week 72 (average of Week 69 and week 73)
Pegvaliase Tmax (Week 73 Intensive PK)
Time to maximum observed plasma concentration (Tmax) for pegvaliase during the Week 73 intensive PK assessment, defined as the elapsed time from dosing to the sampling time at which the highest observed pegvaliase plasma concentration (Cmax) occurs based on the Week 73 plasma concentration-time profile. Pharmacokinetic (PK)
Time frame: Week 73
Pegvaliase Cmax (Week 73 Intensive PK)
Maximum observed plasma concentration (Cmax) of pegvaliase during the Week 73 intensive PK assessment, defined as the highest measured pegvaliase plasma concentration across the Week 73 postdose sampling interval. Cmax is summarized in ng/mL concentration units based on observed values from the Week 73 concentration-time profile.
Time frame: Week 73
Pegvaliase AUC0-24 (Week 73 Intensive PK)
Area under the plasma concentration-time curve from 0-24 hours postdose (AUC0-24) for pegvaliase during the Week 73 intensive PK assessment. AUC0-24 was calculated form the Week 73 plasma concentration-time data using noncompartmental methods and reported in ng\*h/mL units.
Time frame: Week 73
Pegvaliase Cavg (Week 73 Intensive PK)
Average plasma concentration over the 0 to 24 hour postdose interval for pegvaliase during the Week 73 intensive PK assessment, reported in ng/mL concentration units, representing the mean pegvaliase exposure across the 24 hour postdose interval at Week 73.
Time frame: Week 73
Overall: Incidence of Treatment-emergent Adverse Events (Including Part 2)
Time frame: Up to Week 153
Part 2: Percentage of Participants With Anti-pegvaliase Total Antibody (TAb), Positive PAL IgG Antibody, Positive PAL IgM Antibody, Positive PEG IgG Antibody, Positive PEG IgM Antibody and Positive Neutralizing Antibodies (NAb)
Time frame: Baseline (Day 1), Week 145
Part 2: Pegvaliase Tmax, Cmax, AUC0-24 and Cavg (Week 145 Intensive PK)
Time frame: Week 145
This study was conducted by 13 principal investigators at 13 study centers in the United States of America and 3 principal investigators at 3 study centers in Germany.
| Milestone | Experimental: Pegvaliase (Part 1 and Part 2) | Control: Diet Only (Part 1) Then Pegvaliase Treatment (Part 2) |
|---|---|---|
| Started | 36 | 19 |
| Completed | 32 | 17 |
| Not completed | 4 | 2 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Milestone | Experimental: Pegvaliase (Part 1 and Part 2) | Control: Diet Only (Part 1) Then Pegvaliase Treatment (Part 2) |
|---|---|---|
| Started | 32 | 16 |
| Completed part 1, did not enter part 2, continuing in study | 0 | 1 |
| Completed | 0 | 0 |
| Not completed | 32 | 16 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Continuing in study | 31 | 15 |
The blood Phe measurement following 72 weeks on study is defined as the average of the Week 69 and Week 73 blood Phe measurements. Change from baseline in blood Phe will be compared between participants in the active (pegvaliase) and the control (diet-only) treatment arms. Baseline blood Phe concentration at Part 1 was defined as the average of 3 pre-treatment measurements collected between Screening/Run-in (2) and Day 1 pre-dose (1).
| µmol/L | Experimental: Pegvaliase | Control: Diet Only |
|---|---|---|
| Change From Baseline in Blood Phe Concentration Following 72 Weeks (Average of the Week 69 and Week 73) on Study. | -449.9 ± 292.33 | -34.4 ± 272.07 |
Treatment-emergent adverse events (TEAE) is defined as any AE that newly appeared or worsened in severity after first dose of pegvaliase (pegvaliase arm) or on or after study day 1 (diet-only arm) until 30 days after last dose of the study. Serious adverse event (SAE).
| Participants | Experimental: Pegvaliase | Control: Diet Only |
|---|---|---|
| Participants with Any AE | 36 | 17 |
| AEs assessed by investigator as related to study drug | 36 | 0 |
| AEs leading to dose reduction | 9 | 0 |
| AEs leading to dose interruption | 19 | 0 |
| AEs leading to study drug discontinuation | 2 | 0 |
| AEs leading to study discontinuation | 1 | 0 |
| Participants with Any SAE | 2 | 1 |
| SAEs assessed by investigator as related to study drug | 2 | 0 |
| SAEs leading to dose reduction | 0 | 0 |
| SAEs leading to dose interruption | 0 | 0 |
| SAEs leading to study drug discontinuation | 2 | 0 |
| SAEs leading to study discontinuation | 1 | 0 |
| Participants who died | 0 | 0 |
The anti-pegvaliase total antibody (TAb) method captures drug-binding antibodies comprised of different isotypes and specificities. Antibody Positivity = number of subjects testing positive at any study visit / total number of subjects at study visit. The baseline was defined as the last non-missing measurement collected prior to the first pegvaliase dose (pegvaliase arm) or prior to or on Visit 1 date (diet-only arm)
| percentage of participants | Experimental: Pegvaliase |
|---|---|
| Day 1 | 100 |
| Week 73 | 100 |
The presence of immunoglobulin G (IgG) Antibodies against phenylalanine ammonia lyase (PAL) is measured overtime. The baseline was defined as the last non-missing measurement collected prior to the first pegvaliase dose (pegvaliase arm) or prior to or on Visit 1 date (diet-only arm)
| percentage of participants | Experimental: Pegvaliase |
|---|---|
| Day 1 | 22.2 |
| Week 73 | 100 |
The presence of immunoglobulin M (IgM) Antibodies against PAL (phenylalanine ammonia lyase) is measured overtime. PAL IgM was positive if the titer value was greater than or equal to the median of all baseline PAL IgM titers. The baseline was defined as the last non-missing measurement collected prior to the first pegvaliase dose (pegvaliase arm) or prior to or on Visit 1 date (diet-only arm)
| percentage of participants | Experimental: Pegvaliase |
|---|---|
| Day 1 | 50.0 |
| Week 73 | 74.2 |
The presence of IgG Antibodies against polyethylene glycol (PEG) is measured overtime The baseline was defined as the last non-missing measurement collected prior to the first pegvaliase dose (pegvaliase arm) or prior to or on Visit 1 date (diet-only arm)
| percentage of participants | Experimental: Pegvaliase |
|---|---|
| Day 1 | 55.6 |
| Week 73 | 3.2 |
The presence of IgM Antibodies against PEG (polyethylene glycol) is measured overtime The baseline was defined as the last non-missing measurement collected prior to the first pegvaliase dose (pegvaliase arm) or prior to or on Visit 1 date (diet-only arm)
| percentage of participants | Experimental: Pegvaliase |
|---|---|
| Day 1 | 100 |
| Week 73 | 100 |
Neutralizing antibodies (NAbs) capable of inhibiting the enzymatic activity of pegvaliase were measured. The baseline was defined as the last non-missing measurement collected prior to the first pegvaliase dose (pegvaliase arm) or prior to or on Visit 1 date (diet-only arm)
| percentage of participants | Experimental: Pegvaliase |
|---|---|
| Day 1 | 8.3 |
| Week 73 | 96.7 |
The total dietary protein intake following 72 weeks on study is defined as the mean total dietary protein intake calculated from the 3-day diet diaries collected at Week 69 and Week 73 visits. Total dietary protein is measured in grams/kilogram (g/kg). Baseline total protein intake at Part 1 was defined as the mean total dietary protein intake calculated from the 3 separate 3-day diet diaries collected during Screening/Run-in (2) and Day 1 (1).
| g/kg | Experimental: Pegvaliase | Control: Diet Only |
|---|---|---|
| Total Protein Intake | 0.00 ± 0.267 | 0.01 ± 0.226 |
| From Medical Food | -0.20 ± 0.341 | 0.03 ± 0.216 |
| From Intact Food | 0.21 ± 0.369 | -0.02 ± 0.066 |
The total dietary protein intake following 72 weeks on study is defined as the mean total dietary protein intake calculated from the 3-day diet diaries collected at Week 69 and Week 73 visits. Total dietary protein is measured in grams/kilogram (g/kg). Baseline total protein intake at Part 1 was defined as the mean total dietary protein intake calculated from the 3 separate 3-day diet diaries collected during Screening/Run-in (2) and Day 1 (1).
| percentage change | Experimental: Pegvaliase | Control: Diet Only |
|---|---|---|
| Total Protein Intake | 6.66 ± 32.249 | 10.68 ± 43.144 |
| From Medical Food | -28.79 ± 42.498 | 21.56 ± 73.388 |
| From Intact Food | 106.66 ± 176.008 | -10.00 ± 22.828 |
Time to maximum observed plasma concentration (Tmax) for pegvaliase during the Week 73 intensive PK assessment, defined as the elapsed time from dosing to the sampling time at which the highest observed pegvaliase plasma concentration (Cmax) occurs based on the Week 73 plasma concentration-time profile. Pharmacokinetic (PK)
| hrs | Experimental: Pegvaliase |
|---|---|
| Pegvaliase 20 mg | 12.0 ± NA |
| Pegvaliase 40 mg | 10.7 ± 5.08 |
| Pegvaliase 60 mg | 8.66 ± 6.04 |
Maximum observed plasma concentration (Cmax) of pegvaliase during the Week 73 intensive PK assessment, defined as the highest measured pegvaliase plasma concentration across the Week 73 postdose sampling interval. Cmax is summarized in ng/mL concentration units based on observed values from the Week 73 concentration-time profile.
| ng/mL | Experimental: Pegvaliase |
|---|---|
| Pegvaliase 20 mg | 2330 ± NA |
| Pegvaliase 40 mg | 2480 ± 3810 |
| Pegvaliase 60 mg | 1750 ± 2200 |
Area under the plasma concentration-time curve from 0-24 hours postdose (AUC0-24) for pegvaliase during the Week 73 intensive PK assessment. AUC0-24 was calculated form the Week 73 plasma concentration-time data using noncompartmental methods and reported in ng\*h/mL units.
| h*ng/mL | Experimental: Pegvaliase |
|---|---|
| Pegvaliase 20 mg | 46600 ± NA |
| Pegvaliase 40 mg | 17000 ± 27500 |
| Pegvaliase 60 mg | 23200 ± 34000 |
Average plasma concentration over the 0 to 24 hour postdose interval for pegvaliase during the Week 73 intensive PK assessment, reported in ng/mL concentration units, representing the mean pegvaliase exposure across the 24 hour postdose interval at Week 73.
| ng/mL | Experimental: Pegvaliase |
|---|---|
| Pegvaliase 20 mg | 1940 ± NA |
| Pegvaliase 40 mg | 2740 ± 4300 |
| Pegvaliase 60 mg | 1550 ± 2070 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over Up to Week 73 (Part 1). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental: Pegvaliase | 0/36 (0%) | 2/36 (5.6%) | 36/36 (100%) |
| Control: Diet Only | 0/19 (0%) | 1/19 (5.3%) | 17/19 (89.5%) |
| Event | Experimental: Pegvaliase | Control: Diet Only |
|---|---|---|
| Anaphylactic reactionImmune system disorders | 2/36 | 0/19 |
| HyperphenylalaninaemiaCongenital, familial and genetic disorders | 0/36 | 1/19 |
| Event | Experimental: Pegvaliase | Control: Diet Only |
|---|---|---|
| Injection site erythemaGeneral disorders | 28/36 | 0/19 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 27/36 | 1/19 |
| HeadacheNervous system disorders | 24/36 | 8/19 |
| Injection site painGeneral disorders | 22/36 | 0/19 |
| Injection site pruritusGeneral disorders | 19/36 | 0/19 |
| Injection site swellingGeneral disorders | 17/36 | 0/19 |
| PyrexiaGeneral disorders | 15/36 | 1/19 |
| Upper respiratory tract infectionInfections and infestations | 15/36 | 7/19 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/36 | 7/19 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 9/36 | 7/19 |
The Intent to Treat (ITT) population will consist of all participants who are randomized. Participants will be analyzed according to the randomized treatment for the analysis of efficacy.
| Age, Continuous(years) | Experimental: Pegvaliase | Control: Diet Only | Total |
|---|---|---|---|
| Mean | 14.4 ± 1.27 | 14.1 ± 1.29 | 14.3 ± 1.27 |
| Age, Customized(Participants) | Experimental: Pegvaliase | Control: Diet Only | Total |
|---|---|---|---|
| 12 years | 3 | 4 | 7 |
| 13 years | 5 | 0 | 5 |
| 14 years | 12 | 7 | 19 |
| 15 years | 10 | 6 | 16 |
| 16 years | 4 | 2 | 6 |
| 17 years | 2 | 0 | 2 |
| Sex: Female, Male(Participants) | Experimental: Pegvaliase | Control: Diet Only | Total |
|---|---|---|---|
| Female | 22 | 11 | 33 |
| Male | 14 | 8 | 22 |
| Ethnicity (NIH/OMB)(Participants) | Experimental: Pegvaliase | Control: Diet Only | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 2 |
| Not Hispanic or Latino | 34 | 19 | 53 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Experimental: Pegvaliase | Control: Diet Only | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 2 |
| White | 30 | 18 | 48 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 1 | 4 |
| Region of Enrollment(participants) | Experimental: Pegvaliase | Control: Diet Only | Total |
|---|---|---|---|
| United States | 28 | 16 | 44 |
| Germany | 8 | 3 | 11 |
| BMI(kg/m^2) | Experimental: Pegvaliase | Control: Diet Only | Total |
|---|---|---|---|
| Mean | 24.9 ± 5.43 | 24.0 ± 6.33 | 24.6 ± 5.71 |
| Blood Phe Concentration(µmol/L) | Experimental: Pegvaliase | Control: Diet Only | Total |
|---|---|---|---|
| Mean | 1025.3 ± 254.05 | 1028.6 ± 199.39 | 1026.4 ± 234.70 |
7 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2022 to primary completion in Jan 2025, 30 months.
Results were first posted in Jul 2026, 1 year 6 months after primary completion. A results delay was requested in Jul 2025.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegvaliase